- Pace Life Sciences has reopened its 33,000 sq ft Salem, New Hampshire facility as a Centre of Excellence for aseptic fill-finish.
- The upgraded site supports cGMP manufacturing for vaccines, gene therapies, antibodies, and protein-based therapeutics with EU Annex 1 compliance.
Pace® Life Sciences, a U.S.-based contract research, development, and manufacturing organisation (CRDMO) and FDA-registered GMP analytical testing laboratory, has reopened its 33,000 square foot facility in Salem, New Hampshire. The upgraded site now serves as a Centre of Excellence for aseptic fill-finish, designed to meet growing global demand for injectable products.
Equipped with advanced technologies, the facility supports small batch manufacturing under cGMP standards, with the highest level of sterility assurance and compliance with EU Annex 1 guidelines. It is capable of producing vaccines, gene therapies, antibodies, and protein-based therapeutics for clinical use.
According to the company, the site enhancements allow for greater flexibility in production, offering both manual and automated filling for varied batch sizes. Additional capabilities include formulation development, analytical development, and sterile clinical supply manufacturing, enabling Pace Life Sciences to provide integrated contract manufacturing support.
Dawn Von Rohr, President of Pace Life Sciences, said: “This investment reflects our unwavering commitment to our partners, as we work towards accelerating the delivery of medicines into the clinical setting faster. What inspires me most is knowing the real impact this site will have in our shared goal of accelerating the availability of high-quality medicines to improve human health.”
